ClinicaliQ Trial Snapshot
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study — Recruiting • Phase III • Oncology • NCT05862285.
- What is being tested: Continued treatment with Roche investigational medicinal products (IMPs), either as monotherapy or in combination with other agents or comparators, in eligible cancer patients who were previously enrolled in Roche-sponsored clinical trials and remain on active study treatment.
- Patient eligibility overview: Participants must have been enrolled in a prior Genentech and/or F. Hoffmann-La Roche sponsored study, currently be receiving study treatment, and meet criteria for continued treatment benefit without unacceptable safety concerns that would necessitate study discontinuation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP[s]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Eligibility Snapshot
- : * Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR * Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent * First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study * Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator * Ability to comply with the extension study protocol, per Investigator's judgement
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.